2. Search Result
Search Result
Results for "

USP7 inhibitor

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13487
    USP7/USP47 inhibitor
    3 Publications Verification

    		 Deubiquitinase Cancer
    USP7/USP47 inhibitor is a selective ubiquitin-specific protease 7/47 (USP7/USP47) inhibitor, with EC50s of 0.42 μM and 1.0 μM, respectively.
    <em>USP7</em>/<em>USP</em>47 <em>inhibitor</em>
  • HY-148482
    USP7-IN-11

    		Deubiquitinase Cancer
    USP7-IN-11 is a potent ubiquitin-specific protease 7 (USP7) (Deubiquitinase) inhibitor with an IC50 of 0.37 nM. USP7-IN-11 has anticancer effects (WO2022048498A1; Example 187) .
    USP7-IN-11
  • HY-134817
    USP7-IN-8

    		Deubiquitinase Cancer
    USP7-IN-8 (example 81) is a selective ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 of 1.4 μM in an Ub-Rho110 assay. USP7-IN-8 shows no activity against USP47 and USP5. USP7-IN-8 has anticancer effects .
    USP7-IN-8
  • HY-112128
    USP7-IN-3

    		Deubiquitinase Cancer
    USP7-IN-3 (Compound 5) is a potent and selective allosteric ubiquitin-specific protease 7 (USP7) inhibitor .
    USP7-IN-3
  • HY-153942
    USP7-IN-12

    		Deubiquitinase Cancer
    USP7-IN-12 (compound 1) is a potent and orally active Usp7 inhibitor with an IC50 value of 3.67 nM. USP7-IN-12 shows antiproliferative activity .
    USP7-IN-12
  • HY-136910
    USP7-IN-7

    		Deubiquitinase Cancer
    USP7-IN-7 (compound 124) is a USP7 inhibitor with an IC50 value ＜10 nM. USP7-IN-7 shows cytotoxicity against p53-mutant cancer cell lines, p53 wild-type blood cancer and neuroblastoma cell lines with low nanomolar values. USP7-IN-7 can be used for cancer research .
    USP7-IN-7
  • HY-148481
    USP7-IN-10

    		Deubiquitinase Cancer
    USP7-IN-10 (compound 1) is a potent ubiquitin-specific protease 7 (USP7) inhibitor, with an IC50 of 13.39 nM .
    USP7-IN-10
  • HY-148481A
    USP7-IN-10 hydrochloride

    		Deubiquitinase Cancer
    USP7-IN-10 hydrochloride (compound 1) is a potent ubiquitin-specific protease 7 (USP7) inhibitor, with an IC50 of 13.39 nM .
    USP7-IN-10 hydrochloride
  • HY-16709
    USP7-IN-1
    4 Publications Verification

    		 Deubiquitinase Cancer
    USP7-IN-1 is a selective and reversible inhibitor of ubiquitin-specific protease 7 (USP7), with an IC50 of 77 μM, and can be used for the research of cancer.
    USP7-IN-1
  • HY-160515
    USP7-IN-13

    		Deubiquitinase Cancer
    USP7-IN-13 (Compound 101) is a USP7 inhibitor with an IC50 value of 0.2-1 μM, which can be used for the study of multiple myeloma .
    USP7-IN-13
  • HY-146887
    USP7-IN-9

    		Deubiquitinase Apoptosis Cancer
    USP7-IN-9 is a highly potent ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 value of 40.8 nM. USP7-IN-9 can induce apoptosis and arrest cell progression at G0/G1 and S phases in RS4; 11 cells. USP7-IN-9 reduces the protein levels of oncoproteins MDM2 and DNMT1 and increases the protein levels of tumor suppressors p53 and p21 .
    USP7-IN-9
  • HY-129169
    USP7-IN-6

    		Deubiquitinase Cancer
    USP7-IN-6 is a potent ubiquitin specific protease 7 (USP7) inhibitor, extracted from patent WO2017212010A1, example 25, has an IC50 of 6.8 nM .
    USP7-IN-6
  • HY-122886
    XL 188

    		Deubiquitinase Cancer
    XL 188 is a potent and selective USP7 inhibitor with IC50 values of 90 nM and 193 nM for USP7 full-length and catalytic domain enzyme, respectively. XL 188 can be used in research of cancer .
    XL 188
  • HY-112937
    GNE-6640
    2 Publications Verification

    		 Deubiquitinase Cancer
    GNE-6640 is a selective and non-covalent inhibitor of ubiquitin epecific peptidase 7 (USP7), with IC50 values of 0.75 μM, 0.43 μM, 20.3 μM and 0.23 μM for full length USP7, USP7 catalytic domain, full length USP43 and Ub-MDM2, respectively .
    GNE-6640
  • HY-101666
    HBX 41108
    1 Publications Verification

    		 Deubiquitinase Apoptosis MDM-2/p53 Metabolic Disease Cancer
    HBX 41108 is an inhibitor of ubiquitin-specific protease 7 (USP7) with an IC50 of 424 nM. HBX 41108 inhibits USP7-mediated p53 deubiquitination to stabilize p53 and inhibits cancer cell growth. BX 41108 can be used in cancer and diabetes research .
    HBX 41108
  • HY-158039
    YCH2823

    		Deubiquitinase Apoptosis Cancer
    YCH2823 is an inhibitor of USP7 (IC50 = 49.6 nM; Kd = 0.117 μM). YCH2823 shows significant efficacy in inhibiting TP53 wild-type and mutant tumors, with approximately 5-fold higher potency than FT671. YCH2823 induce apoptosis. YCH2823 synergistic effects with mTOR inhibitors .
    YCH2823
  • HY-107986
    GNE-6776
    2 Publications Verification

    		 Deubiquitinase Cancer
    GNE-6776 is a selective and orally bioavailable USP7 inhibitor .
    GNE-6776
  • HY-15667
    P005091
    10+ Cited Publications

    P5091

    		 Deubiquitinase Cancer
    P005091 is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with an EC50 of 4.2 μM.
    P005091
  • HY-17540
    HBX 19818
    10+ Cited Publications

    		 Deubiquitinase Cancer
    HBX 19818 is a specific inhibitor of ubiquitin-specific protease 7 (USP7), with an IC50 of 28.1 μM.
    HBX 19818
  • HY-13865
    P 22077
    10+ Cited Publications

    		 Deubiquitinase Cancer
    P 22077 is a cell-permeable ubiquitin-specific protease 7 (USP7) inhibitor with an EC50 of 8.01 μM. P 22077 also inhibits USP47 with an EC50 of 8.74 μM.
    P 22077
  • HY-138794
    XL177A

    		Deubiquitinase Cancer
    XL177A is a highly potent and selective irreversible USP7 inhibitor with an IC50 of 0.34 nM. XL177A elicits cancer cell killing through a p53-dependent mechanism .
    XL177A
  • HY-100708
    NSC632839
    3 Publications Verification

    		 Deubiquitinase Cancer
    NSC632839 is a nonselective isopeptidase inhibitor, which inhibits USP2, USP7, and SENP2 with EC50s of 45±4 μM, 37±1 μM, and 9.8±1.8 μM, respectively.
    NSC632839
  • HY-13814
    PR-619
    10+ Cited Publications

    		 Deubiquitinase Autophagy Apoptosis Cancer
    PR-619 is a broad-range and reversible DUB inhibitor with EC50s of 3.93, 4.9, 6.86, 7.2, and 8.61 μM for USP4, USP8, USP7, USP2, and USP5, respectively. PR-619 induces ER Stress and ER-Stress related apoptosis .
    PR-619
  • HY-13453
    BAY 11-7082
    Maximum Cited Publications
    271 Publications Verification

    BAY 11-7821

    		 IKK Deubiquitinase Autophagy Apoptosis NF-κB Inflammation/Immunology Cancer
    BAY 11-7082 is an IκBα phosphorylation and NF-κB inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC50=0.19, 0.96 μM, respectively). BAY 11-7082 inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells .
    BAY 11-7082
  • HY-149228
    USP28-IN-2

    		Deubiquitinase Cancer
    USP28-IN-2 is a USP28 inhibitor (IC50=0.3 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-2 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-2 also decreases the ankyrase-1/2 level in vitro. USP28-IN-2 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331) .
    USP28-IN-2
  • HY-149229
    USP28-IN-3

    		Deubiquitinase Cancer
    USP28-IN-3 is a USP28 inhibitor (IC50=0.1 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-3 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-3 also decreases the ankyrase-1/2 level in vitro. USP28-IN-3 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331) .
    USP28-IN-3
  • HY-149230
    USP28-IN-4

    		Deubiquitinase Cancer
    USP28-IN-4 is a USP28 inhibitor (IC50=0.04 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-4 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-4 also decreases the ankyrase-1/2 level in vitro. USP28-IN-4 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331) .
    USP28-IN-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: